BOC Sciences provides end-to-end peptide antigen synthesis services for antibody generation, epitope mapping, and immunoassay development programs. Our team converts target protein sequences into chemically defined immunogens through epitope analysis, high-fidelity synthesis, site-specific modification, carrier conjugation, and orthogonal analytical confirmation, so that each antigen batch reliably directs the antibody response to the intended region of the target protein.
Peptide antigen synthesis is the chemical preparation of short, sequence-defined peptides, typically 8-25 amino acids in length, that represent a selected B-cell epitope of a target protein. Unlike recombinant protein immunogens, which expose the entire molecule to the immune system, synthetic peptide antigens focus antibody production on one defined region, such as a unique terminal sequence, a mutation site, or a post-translational modification. Because free peptides are small and weakly immunogenic on their own, they are usually presented on a carrier protein, assembled as a branched multiple antigenic peptide (MAP), or built with a lipid adjuvanting group before immunization.
Compared with full-length protein immunogens, custom peptide synthesis gives antibody programs several practical advantages:
Linear peptide antigens are the standard format for antibodies against continuous B-cell epitopes. BOC Sciences assembles linear antigen peptides by Fmoc solid-phase chemistry, with coupling handles positioned away from the epitope so carrier attachment never masks key residues.
Cyclic antigen peptides constrain a linear sequence into a defined topology, making them powerful immunogens for raising antibodies that recognize structured or conformationally biased regions of the native protein.
MAP constructs display multiple copies of an antigen peptide on a branched lysine core, producing a high-epitope-density immunogen that requires no carrier protein. Built on our branched peptide synthesis platform, this format is particularly effective for short epitopes of 10-20 residues.
Coupling a peptide to a large carrier protein converts a weakly immunogenic hapten into an effective immunogen. BOC Sciences prepares carrier-conjugated antigen peptides through dedicated peptide conjugation services and broader bioconjugation capabilities, with orientation-controlled chemistry and verified peptide loading.
Lipopeptide antigens attach a lipid moiety to an antigen peptide, combining epitope and immune-stimulating function in a single molecule. This self-adjuvanting format strengthens responses to weak epitopes and supports delivery-oriented antigen research.
Post-translationally modified antigens carry a defined modified residue at the epitope center, enabling antibodies that distinguish the modified state of a protein from its unmodified form. These projects extend our modified peptide synthesis services to immunization-grade material.
BOC Sciences helps research teams move from a raw target sequence to a validated immunogen design, covering epitope analysis, synthesis route selection, modification placement, carrier conjugation, and full analytical confirmation.
BOC Sciences supports peptide antigen projects from early epitope analysis through immunogen delivery, with each stage documented and analytically confirmed. Key project stages include:
| Development Stage | Service Scope & Key Outputs |
| Epitope Analysis & Design | Evaluation of the target sequence for hydrophilicity, surface accessibility, flexibility, and family-member uniqueness; shortlisting of candidate epitopes with synthesis difficulty and solubility feedback; design confirmation with the client before synthesis begins. |
| Antigen Peptide Synthesis | Fmoc solid-phase synthesis of linear, cyclic, branched (MAP), and lipidated antigen peptides from screening scale to gram scale, with difficult-sequence strategies applied where the epitope demands them. |
| Modification & Functionalization | Incorporation of phosphorylation, methylation, acetylation, and other modified residues; installation of cysteine or click coupling handles; N- and C-terminal capping and spacer insertion to preserve native-like presentation. |
| Carrier Conjugation | Coupling to KLH, BSA, OVA, and alternative carriers using maleimide, EDC/NHS, or click chemistry, with controlled peptide loading and removal of unconjugated peptide from the final conjugate. |
| Purification & Fractionation | Preparative HPLC purification, fraction comparison, lyophilization, and re-purification or buffer conditioning for batches with solubility or handling constraints. |
| Characterization & QC | Mass confirmation, analytical HPLC purity assessment, peptide-to-carrier ratio measurement, residual free peptide checks, and complete batch documentation for every released antigen. |
| Immunogen & Detection Antigen Preparation | Parallel preparation of immunization antigens (typically KLH conjugates) and screening antigens (typically BSA or OVA conjugates, or labeled peptides) so that ELISA screening avoids anti-carrier background from the outset. |
| Delivery & Project Documentation | Lyophilized peptides or conjugates delivered with certificates of analysis, recommended handling notes, immunization schedule suggestions, and full project records for downstream use. |
Work with BOC Sciences at any stage of your peptide antigen project. We can provide a complete workflow from epitope analysis and sequence optimization through synthesis, modification, carrier conjugation, purification, characterization, and final delivery. Clients can also select individual services based on project needs, including antigen design optimization, synthesis from a provided sequence or structure, peptide modification, carrier conjugation, purification, or analytical characterization.
BOC Sciences reviews the client's target sequence and antibody application, screens candidate epitopes for accessibility, uniqueness, and synthesizability, and confirms the final antigen design, modification pattern, and carrier plan before any synthesis begins.
The peptide is assembled by Fmoc solid-phase synthesis with modified residues and coupling handles built in at defined positions, then purified by preparative HPLC and confirmed by mass spectrometry before moving to conjugation.
The purified peptide is conjugated to the selected carrier or formatted as a MAP or lipopeptide construct. Each batch undergoes peptide loading measurement, purity and residual free peptide checks, and LC-MS/MS confirmation when the project requires modification-site evidence.
Clients receive lyophilized antigen or conjugate, matched control peptides, and certificates of analysis with HPLC and mass data, together with handling notes, formulation guidance, and stability studies support for antigens with known storage sensitivity.
Strongly hydrophobic epitopes, long aliphatic stretches, and aggregation-prone sequences often fail as crude products or dissolve too poorly for conjugation and formulation. BOC Sciences addresses these projects at the design stage: adjusting epitope boundaries by one or two residues, inserting solubilizing flanking sequences, applying pseudoproline and backbone-protection strategies during synthesis, and selecting purification conditions that recover usable material. Where needed, we add solubility analysis and alternative formulation screening so the finished antigen can be handled in immunization-ready buffers.
Short peptides presented poorly can produce low titers or antibodies that only recognize the free peptide. We respond with format-level optimization rather than repeated rounds of immunization: increasing epitope density through MAP or multi-epitope designs, selecting carriers with strong immunostimulating performance, positioning coupling sites away from the epitope, and supplying two or three parallel antigen candidates so the strongest responder can be identified early in the program.
Antibodies raised against conserved regions frequently bind related family members and produce ambiguous assay data. Our design process screens every candidate epitope against sequence databases, prioritizes regions of divergence between family members, places distinguishing residues at the epitope center rather than the edge, and recommends negative-selection peptides for serum adsorption when homology cannot be avoided.
Linear peptide antibodies sometimes bind the free peptide but not the folded target, because the epitope is buried or conformationally constrained in the native protein. BOC Sciences mitigates this risk by favoring surface-exposed flexible loop regions during epitope selection, constraining the antigen through cyclization or stapling when a structured epitope is the goal, and providing both peptide and protein-compatible screening antigens so binding to the native form can be tracked from the first immunization bleed.
Difficult sequences, complex modifications, and purification can all complicate peptide antigen development. BOC Sciences brings together experienced peptide synthesis scientists, versatile synthesis and analytical platforms, and a broad range of amino acid derivatives, resins, coupling reagents, linkers, and conjugation materials to troubleshoot challenging projects and develop practical synthesis solutions.
Every project opens with an epitope analysis and design discussion rather than a simple synthesis order. Project scientists with peptide chemistry and immunology backgrounds stay with the project from design to delivery, so the design intent is preserved through synthesis, conjugation, and QC instead of being lost between handoffs.
Modified building blocks, spacer and linker chemistry, carrier conjugation, and custom synthesis of special reagents are handled in-house. This removes the multi-vendor handoffs where antigen design details are most often lost, and gives clients one accountable team for the entire immunogen.
Each antigen is released with mass identity data and analytical HPLC purity results, and conjugates receive loading-ratio and residual free peptide checks. Our broader analytical platform supports NMR, HRMS, and additional chromatographic methods when a project requires deeper characterization.
From microgram-scale screening peptides to gram-scale immunogen resupply, and from free peptides to KLH, BSA, MAP, and lipopeptide formats, the workflow scales with the program. Additional biomolecule labeling options such as biotin and fluorescent tags extend the same antigen sequence into detection applications.
Client Needs: A membrane-protein research group needed a peptide immunogen from a 17-residue juxtamembrane region containing several Leu, Ile, Val, and Phe residues. The client required a KLH-conjugated antigen for immunization and unconjugated peptide for later antibody screening.
Challenges: The native sequence showed strong hydrophobicity, poor swelling during test synthesis, broad crude HPLC behavior, and precipitation during aqueous handling. Direct addition of a terminal Cys without a spacer also placed the carrier too close to residues expected to contribute to antibody recognition.
Solution: We compared two resin loadings and three coupling programs, then selected a low-loading Fmoc-SPPS route with repeat coupling at the most hindered residues. An Ahx-Cys handle was introduced at the noncritical terminus. The peptide was purified by modified RP-HPLC, confirmed by LC-MS, and conjugated to KLH through thiol-maleimide chemistry after screening two solvent-compatible coupling conditions.
Outcome: The project produced a defined free peptide and corresponding KLH conjugate with improved handling compared with the initial synthesis attempt, giving the client matched immunization and screening reagents based on the same epitope sequence.
Client Needs: A signal-transduction team required an antigen pair centered on a phosphorylation site within a kinase substrate. The goal was to generate antibodies able to distinguish the phosphorylated Ser-containing sequence from the same local sequence in its unmodified state.
Challenges: The target region contained neighboring Ser and Thr residues that could complicate interpretation if the antigen design were too short. The phosphopeptide also showed different chromatographic behavior from the unmodified control, making matched purification and quantitative comparison important.
Solution: We synthesized matched 15-mer peptides by Fmoc-SPPS, incorporating protected phosphoserine directly into the modified sequence while keeping all flanking residues identical. A terminal spacer-Cys handle was placed away from the phosphorylation site. Both peptides were purified independently, checked by HPLC and LC-MS, and the phosphopeptide was coupled to KLH while the unmodified peptide was retained for competitive specificity testing.
Outcome: The client received a structurally matched antigen/control pair that allowed immunization with the phosphorylated epitope and direct assessment of phosphorylation-dependent versus sequence-only antibody binding.
Client Needs: A protein-interaction laboratory needed an antibody against the native free C terminus of a signaling protein. Because the terminal carboxyl group was part of the recognition requirement, conventional C-terminal attachment to a MAP core would have masked the feature the antibody needed to distinguish.
Challenges: The 13-residue C-terminal sequence was short and moderately acidic. A standard branched SPPS MAP would anchor the peptide through its C-terminal end, creating an antigen with the wrong terminal presentation and risking antibodies directed toward an artificial internalized terminus.
Solution: We synthesized the 13-mer with its native free C-terminal carboxyl group and installed an N-terminal Ahx-based coupling handle. Four peptide copies were then assembled onto a prefunctionalized lysine-core scaffold through the N termini. The monomer precursor was verified by HPLC and LC-MS, and the final four-branch construct was assessed by mass-based analysis and comparative chromatographic profiling before delivery.
Outcome: The resulting MAP displayed multiple copies of the epitope while preserving the native free C terminus, giving the client an antigen format aligned with the desired terminal-specific antibody recognition.
There is no single optimal length for every peptide antigen. In many antibody-generation projects, peptides in the mid-teen amino-acid range provide a practical balance between epitope coverage, synthesis feasibility, solubility, and sequence specificity. Shorter peptides can focus the immune response on a narrowly defined region but may provide limited antigenic presentation, while longer sequences can introduce additional epitopes, secondary structure, hydrophobicity, or cross-reactive regions. The final length should therefore be selected according to protein location, surface accessibility, sequence uniqueness, modification sites, terminal requirements, and the intended antibody application.
Carrier conjugation is commonly considered when a synthetic peptide is too small to provide effective antigen presentation on its own. The choice should not be based only on peptide length. Sequence composition, solubility, epitope accessibility, intended immunization strategy, and downstream assay design also matter. Equally important is how the peptide is attached. N-terminal, C-terminal, or side-chain coupling can expose different parts of the epitope, while an appropriate spacer can reduce steric masking by the carrier. For some projects, a carrier-conjugated antigen is prepared for immunization together with free peptide or an alternate conjugate for subsequent antibody screening.
Modified peptide antigens are typically designed so that the phosphorylation, methylation, acetylation, or other target modification is positioned within sufficient native flanking sequence for antibody recognition. The modification should also remain accessible rather than being placed close to the carrier attachment site. For specificity studies, a matched unmodified peptide is highly useful because it allows direct comparison between modification-dependent binding and binding to the underlying amino-acid sequence. Sequence homology around the modification site should also be reviewed to identify related proteins or isoforms that could contribute to cross-reactivity.
Yes. BOC Sciences can evaluate difficult peptide antigens before or during synthesis and develop a project-specific strategy based on the source of the problem. Hydrophobic sequences, aggregation-prone regions, repeated residues, sterically hindered coupling sites, multiple cysteines, complex modifications, cyclization, and poor chromatographic behavior may require different solutions. Our scientists can adjust peptide boundaries when biologically acceptable, resin and protection strategies, coupling cycles, solvent systems, cleavage conditions, purification methods, spacer design, and conjugation chemistry. Synthesis and analytical platforms are used together so that problems can be identified and addressed at the appropriate stage rather than treated with a single standard protocol.
Yes. BOC Sciences supports both complete peptide antigen development and standalone project stages. Clients can work with us from epitope analysis and sequence optimization through peptide synthesis, modification, carrier conjugation, purification, analytical characterization, and final delivery, or select only the services they need. For example, you may provide a defined sequence for synthesis, send an existing peptide for carrier conjugation, request optimization of a difficult antigen design, order a modified/unmodified peptide pair, or use us only for purification or analytical confirmation. This flexible model allows the project scope to match your existing materials, internal capabilities, and research objectives.
BOC Sciences analyzed our target against the whole protein family before synthesis and steered us to an epitope we had not considered. The resulting sera distinguish the two subtypes directly, which saved us weeks of adsorption work.
— Dr. Lewis, Antibody Development Lead
The phosphorylated and unphosphorylated peptides arrived as a matched set with both KLH and BSA conjugates in one project. Screening was clean from the first round, and the documentation made data review straightforward.
— Dr. Roberts, Principal Scientist, Signaling Research
Ordering the immunization antigen and the ELISA coating antigen from the same team removed the batch-mismatch problems we had before. Background dropped noticeably once anti-carrier signal was designed out of the assay.
— Dr. Young, Head of Assay Development
We received updates at design confirmation, synthesis, conjugation, and QC, with reports available whenever we asked. When one candidate epitope proved difficult, the team proposed and executed an alternative route without delaying the program.
— Torres, Program Manager, Protein Sciences
If you have any questions or encounter issues on this page, please don't hesitate to reach out. Our support team is ready to assist you.
